Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
Recent Posts
Enterprises portfolio company, Curavi Health, acquires TripleCare
Since its inception in 2016, Curavi Health has focused on addressing the care gaps in …
Read More →
What is the secret sauce of a health care startup?
Last month, Fast Company published an article looking at trends in the digital health startup space and comparing the traits of consumer based tech companies to health care startups.
Read More →